Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MTO-S1
- Development stage
- Preclinical
- Lead developer
- Biotts
- Modality
- Peptides, Small Molecules
- Administration
- Transdermal
01
Overview
MTO-S1 is a preclinical-stage transdermal patch being developed by Biotts for the treatment of diabetes. The drug utilizes Biotts' proprietary MTC-Y (Multicomponent Transport System) technology, which is designed to enable the transdermal delivery of active pharmaceutical ingredients that typically have low skin permeability, including large molecules like peptides and proteins. By delivering the medication through the skin, MTO-S1 aims to provide a non-invasive alternative to injections or a more controlled release compared to oral formulations, potentially improving patient compliance and reducing systemic side effects associated with traditional delivery methods.
02
Targets
Beyond the preview
Go deeper on MTO-S1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MTO-S1.